Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Wedbush ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Looking ahead, ...

SAN DIEGO — SAN DIEGO — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $47.7 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 40 cents ...